Pharmaceuticals
Malaysia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Malaysia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $ 1.8 Mn in 2022, and is predicted to grow at (CAGR) of 6% from 2023 to 2030, to US $ 2.9 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, government initiatives, advanced treatment options and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus among others
Buy Now
Malaysia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The Malaysia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market is at around US $1.8 Mn in 2022 and is projected to reach US $2.9 Mn in 2030, exhibiting a CAGR of 6% during the forecast period.
ADPKD is a genetic condition caused by PKD1 and PKD2 gene mutations that results in the formation of fluid-filled cysts in the kidneys. These cysts frequently develop, resulting in renomegaly and, eventually, renal failure in most patients. ADPKD is characterized by symptoms such as pain, exhaustion, urinary tract infections, and others. While there is no cure for ADPKD, numerous therapies are available to help with symptom management and disease progression. Otsuka Pharmaceuticals' tolvaptan (Jinarc) is the only approved medication for ADPKD. It works as a vasopressor and has been shown to reduce cyst formation in some patients. Pain management and lifestyle changes are additional treatment possibilities.
Malaysia is a country located in Southeast Asia. Estimates suggest that the prevalence of ADPKD is 15.5% in Malaysia. The prevalence of ADPKD in Malaysia is predicted to rise because of advances in diagnostic methods that reduce the likelihood of missed detections, a favourable regulatory landscape that allows for the rapid approval of innovative treatments, and increased investment in curative and preventive research. The market is therefore driven by major factors like the increased prevalence of ADPKD, government initiatives for chronic medical assistance, and advanced treatment options in the industry. However, conditions such as high costs of treatment, limited awareness, underdiagnosis, and others hinder the growth and potential of the market.
Market Dynamics
Market Growth Drivers
Surge in the prevalence of ADPKD: In Malaysia, it is reported that the prevalence of CKD has increased from 9.1% in 2011 to 15.5% and accounts for 9.07% of the total Malaysian population. These numbers are steadily rising, resulting in patients requiring advanced treatments, resulting in the growth of the market.
Government initiatives: The Malaysian government's emphasis on enhancing healthcare accessibility and affordability via initiatives like PeKa B40, which provides health benefits to low-income populations, and the Chronic Medical Assistance Scheme (Skim Bantuan Perubatan Kronik) offers financial assistance to ADPKD patients, potentially improving treatment access. Programs targeting chronic illnesses, such as the National Strategic Plan for Non-Communicable Diseases (2016–2025), indicate future policy advancements that benefit ADPKD management and allow market expansion.
Advanced treatment options: The introduction of innovative treatments like gene therapy and targeted medicines allows for better prevention and potential curative prospects, attracting top pharmaceutical companies and market investors. Crafting personalized medicine strategies designed for distinct ADPKD genotypes could additionally broaden the market by offering tailored treatment options. Groups such as the Malaysian Society of Nephrology and portals like the National Renal Registry work towards improving patient access and care, influencing evidence-based policy decisions by gathering data that propels the therapeutics market.
Market Restraints
High costs of treatment: Tolvaptan, the existing primary medication for ADPKD, alongside potential upcoming therapies, still pose considerable financial challenges for patients despite SOCSO and Medcard coverage. This could burden patients financially, potentially limiting treatment accessibility and leading to non-adherence or delays, affecting the market's outreach.
Limited awareness and underdiagnosis:Lack of awareness regarding ADPKD symptoms and the significance of early diagnosis could lead to missed chances for intervention and exacerbate disease advancement. This constraint affects the market scope and the need for treatments. Furthermore, restricted availability of advanced diagnostic tools, especially in rural regions, contributes to underdiagnosis and delays in receiving essential treatment.
Healthcare system disparities: The healthcare system in Malaysia, amidst developments, presents complexities leading to inequalities in accessing specialists, medications, and reimbursement processes. These factors might delay prompt access to suitable ADPKD treatment for certain patients, impeding market expansion. Additionally, government healthcare initiatives might not entirely cover the expenses for all required ADPKD treatments, necessitating patients to bear out-of-pocket cost digressing the market's growth.
Notable updates
August, 2023, The MOH initiated a nationwide campaign about chronic kidney diseases, integrating resources and information about ADPKD. This initiative serves to educate the public and potentially promote earlier detection of the condition.
April, 2023, The Ministry of Health (MOH) established a group of experts to address rare conditions such as ADPKD. This initiative intends to raise disease awareness, improve access to diagnosis and treatment, and potentially shorten future regulatory procedures for novel therapeutics.
Healthcare Policies and Regulatory Landscape
Malaysia's healthcare policy and regulatory framework comprise a number of important bodies and organizations. The Ministry of Health (MOH) is the major institution in Malaysia responsible for healthcare legislation and licensing. The MOH is in charge of developing national health policy, coordinating medical and healthcare reform, and overseeing the administration of healthcare services throughout Malaysia.
Acquiring a license for healthcare items in Malaysia entails compliance with MOH and other agencies, such as the Malaysian Medical Council laws. These organizations are in charge of overseeing and supervising healthcare services, as well as approving and monitoring medical and healthcare products. Companies must get approval from the MOH in order to register and market pharmaceuticals and medical devices. This procedure entails submitting technical and scientific data in order to validate the product's safety, quality, and functionality.
Malaysia's healthcare policy and regulatory system involve a number of authorities and agencies, with the Ministry of Health playing a critical role in healthcare product regulation. The country's governmental and private healthcare industries both provide numerous prospects for healthcare-related companies.
Competitive Landscape
Key Players
- Otsuka Pharmaceutical Co. Ltd
- Regulus Therapeutics
- Palladio Biosciences
- Reata Pharmaceuticals
- Galapagos NV
- Exelixis Inc
- AceLink Therapeutics, Inc
- Sanofi
- Xortx Therapeutics
- Pano Therapeutics
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Malaysia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Segmentation
By Treatment
- Pain & Inflammation Treatment
- Kidney Stone Treatment
- Urinary Tract Infection Treatment
- Kidney Failure Treatment
By Route of Administration
- Oral
- Parenteral
- Others
By End User
- Hospitals
- Speciality Clinics
- Surgical Centres
- Others
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
- Analyzing historical proprietary data collected from multiple projects.
- Regularly updating our existing data sets with new findings and trends.
- Ensuring data consistency and accuracy through rigorous validation processes.
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
- Searching through academic conferences, published research, citations, and social media platforms
- Collecting and compiling diverse data to build a comprehensive and detailed database
- Continuously updating our database with new information to ensure its relevance and accuracy
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
- Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
- Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
- Continuously refreshing our database to ensure that the information remains current and reliable.
- Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
- Merging historical data from secondary research with real-time data from primary research.
- Conducting thorough data validation and cleansing to remove inconsistencies and errors.
- Organizing data into a structured format that is easily accessible and usable for various applications.
- Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
Related reports (by category)
Pharmaceuticals
Vietnam Atopic Dermatitis Therapeutics Market Analysis
Pharmaceuticals
Saudi Arabia Prostate Cancer Drugs Market Analysis
Pharmaceuticals
UAE Cholesterol / Lipid Lowering Drugs Market Analysis
Related reports (by geography)
Pharmaceuticals
Malaysia End-stage Renal Disease(ESRD) Market Analysis
Pharmaceuticals
Malaysia Brugada Syndrome Market Analysis
Pharmaceuticals
